Peter A. Fasching

Researcher Next ID · RN-001945

Researcher · Biochemistry, Genetics and Molecular Biology

Erlangen, Germany

Not currently recruitingFunding unknown

Research interests

Biochemistry, Genetics and Molecular Biology

Medicine

Breast Cancer Treatment Studies

Advanced Breast Cancer Therapies

HER2/EGFR in Cancer Research

BRCA gene mutations in cancer

Ovarian cancer diagnosis and treatment

Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1910549
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1814017
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30904-x
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.8595

No projects listed.